Praxis Precision Medicines to Host PRAX-628 Program Update
25 mars 2024 16h01 HE
|
Praxis Precision Medicines, Inc.
Presentation will be held virtually on Tuesday, March 26, 2024 at 8:00 a.m. ET Praxis leadership will be joined by key opinion leader in epilepsy Dr. Daniel Friedman, Professor of Neurology at...
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
05 mars 2024 07h00 HE
|
Praxis Precision Medicines, Inc.
Over 3,000 referrals received to date meet pre-qualifying eligibility criteria for ulixacaltamide Phase 3 studies in the Essential3 program for essential tremor (ET); enrollment on track to be...
Praxis Precision Medicines to Participate in TD Cowen’s 44th Annual Health Care Conference
01 mars 2024 08h00 HE
|
Praxis Precision Medicines, Inc.
BOSTON, March 01, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 févr. 2024 16h00 HE
|
Praxis Precision Medicines, Inc.
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines, Inc. Announces Pricing of $150.0 Million Public Offering
11 janv. 2024 07h30 HE
|
Praxis Precision Medicines, Inc.
BOSTON, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
10 janv. 2024 16h19 HE
|
Praxis Precision Medicines, Inc.
BOSTON, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines Provides Update on Advancing Clinical Stage Portfolio
08 janv. 2024 08h00 HE
|
Praxis Precision Medicines, Inc.
Positive preliminary analysis of 15 mg cohort in the PRAX-628 study in epilepsy patients with Photo-Paroxysmal Response (PPR) exceeds expectations; topline results expected in 1Q 2024 after completion...
Praxis Precision Medicines Announces Licensing and Collaboration Agreement with Tenacia Biotechnology for Ulixacaltamide in Greater China
05 janv. 2024 08h00 HE
|
Praxis Precision Medicines, Inc.
Collaboration leverages Tenacia’s expertise in central nervous system drug development and commercialization and will address a significant unmet patient need Praxis to receive upfront proceeds of...
Praxis Precision Medicines to Showcase Largest Pipeline of Precision Epilepsy Programs and Breadth of Commitment to Epilepsy Treatments at Upcoming Meetings
28 nov. 2023 07h00 HE
|
Praxis Precision Medicines, Inc.
BOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines to Present at the Piper Sandler 35th Annual Healthcare Conference
21 nov. 2023 16h00 HE
|
Praxis Precision Medicines, Inc.
Praxis Precision Medicines to Present at the Piper Sandler 35th Annual Healthcare Conference